Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "real World" registry

Thrombosis Research

Volumn 135, Issue 6, 2015, Pages 1093-1099

  Motovska, Zuzana ^a   Ondrakova, Martina ^a   Bednar, Frantisek ^a   Knot, Jiri ^a   Ulman, Jaroslav ^a   Maly, Marek ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

High residual platelet reactivity; P2Y12 receptor antagonist; Platelet count; Platelet volume; Predictors; Selection

Indexed keywords

CLOPIDOGREL; CREATININE; HEMOGLOBIN; PRASUGREL; TICAGRELOR; UREA; VASODILATOR STIMULATED PHOSPHOPROTEIN; ADENOSINE; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTICLE; DRUG EFFICACY; HEMOGLOBIN BLOOD LEVEL; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; AGED; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL (TOPIC); CORONARY ANGIOGRAPHY; DRUG DESIGN; DRUG EFFECTS; FEMALE; HOSPITAL ADMISSION; MALE; MIDDLE AGED; PERSONALIZED MEDICINE; PROCEDURES; PROSPECTIVE STUDY; REGISTER; THROMBOCYTE;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; CORONARY ANGIOGRAPHY; DRUG DESIGN; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET COUNT; PRASUGREL HYDROCHLORIDE; PRECISION MEDICINE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; REGISTRIES; TICLOPIDINE;

EID: 84929503625     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.04.014     Document Type: Article

References (36)

1. P.G. Steg, S.K. James, D. Atar, L.P. Badano, C.B. Lundqvist, and M.A. Borger ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J 33 2012 2569 2619
2. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, and H. Bueno ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 32 2011 2999 3054
3. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Beinart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
4. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, L. Nait-Saidi, and J. Carvajal Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting J Am Coll Cardiol 48 2006 1339 1345
5. G. Parodi, R. Marcucci, R. Valenti, A.M. Gori, A. Migliorini, and B. Giusti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 2011 1215 1223
6. I. Mrdovic, L. Savic, G. Krljanac, M. Asanin, J. Perunicic, and N. Antonijevic Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial Int J Cardiol 167 4 2013 1632 1637
7. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
8. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
9. A. Sandhu, M. Seth, S. Dixon, D. Share, D. Wohns, and T. LaLonde Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) Circ Cardiovasc Qual Outcomes 6 2013 293 298
10. L. Wallentin, A. Himmelmann, R.F. Storey, P.G. Steg, and R.A. Harrington PLATO Publications Committee. Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value Thromb Haemost 112 1 2014 12 14
11. European Perspectives in Cardiology Centres of Excellence: the Cardiocentre Prague, Czech Republic Circulation 118 2008 f13 f18 (Suppl.)
12. B. Aleil, C. Ravanat, J.P. Cazenave, G. Rochoux, A. Heitz, and C. Gachet Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases J Thromb Haemost 3 2005 85 92
13. K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, and B.R. Chaitman White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Third universal definition of myocardial infarction Circulation 126 16 2012 2020 2035
14. F. Bonhomme, P. Fontana, and J.L. Reny How to manage prasugrel and ticagrelor in daily practice Eur J Intern Med 25 3 2014 213 220
15. G. Montalescot, L. Bolognese, D. Dudek, P. Goldstein, C. Hamm, and J.F. Tanguay A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study Am Heart J 161 2011 650 656
16. Widimsky P, Motovska Z, Bolognese L, Dudek D, Hamm C, Tanguay JF, ten Berg J, Brown E, LeNarz L, Miller DL, Montalescot G. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel: analysis from the ACCOAST Study. ESC 2014.
17. D. Capodanno, and D.J. Angiolillo Antithrombotic therapy in patients with chronic kidney disease Circulation 125 21 2012 2649 2661
18. S. James, A. Budaj, P. Aylward, K.K. Buck, C.P. Cannon, and J.H. Cornel Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial Circulation 122 11 2010 1056 1067
19. R.C. Becker, J.P. Bassand, A. Budaj, D.M. Wojdyla, S.K. James, and J.H. Cornel Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial Eur Heart J 32 23 2011 2933 2944
20. G. Montalescot, and J. Silvain Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation 122 11 2010 1049 1052
21. S.T. Brookes, E. Whitley, T.J. Peters, P.A. Mulheran, M. Egger, and G. Davey Smith Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives Health Technol Assess 5 33 2001 1 56
22. P.M. Rothwell Subgroup analysis in randomised controlled trials: importance, indications, and interpretation Lancet 365 9454 2005 176 186
23. G. Montalescot, A.W. van't Hof, F. Lapostolle, J. Silvain, J.F. Lassen, and L. Bolognese Prehospital ticagrelor in ST-segment elevation myocardial infarction N Engl J Med 371 11 2014 1016 1027
24. G. Montalescot, L. Bolognese, D. Dudek, P. Goldstein, C. Hamm, and J.F. Tanguay Widimsky P; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes N Engl J Med 369 2013 999 1010
25. P. Kala Heart & brain: STEMI-like network for ischaemic stroke? EuroIntervention 10 7 2014 778 780
26. D. Alexopoulos, I. Xanthopoulou, V. Gkizas, G. Kassimis, K.C. Theodoropoulos, and G. Makris Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
27. C. Gieger, A. Radhakrishnan, A. Cvejic, W. Tang, and E. Porcu New gene functions in megakaryopoiesis and platelet formation Nature 480 7376 2011 201 208
28. C.B. Thompson, D.G. Love, P.G. Quinn, and C.R. Valeri Platelet size does not correlate with platelet age Blood 62 1983 487 494
29. J.F. Martin, J. Plumb, R.S. Kilbey, and Y.T. Kishk Changes in volume and density of platelets in myocardial infarction BMJ 287 1983 456 459
30. I. Pizzulli, A. Yang, J.F. Martin, and B. Lüderitz Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain Eur Heart J 19 1998 80 84
31. J.F. Martin, S.D. Kristensen, A. Mathur, E.L. Grove, and F.A. Choudry The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes Nat Rev Cardiol 9 2012 658 670
32. T. Wong, L. Pedvis, and M. Frojmovic Platelet size affects both micro- and macro-aggregation: contributions of platelet number, volume fraction and cell surface Thromb Haemost 62 2 1989 733 741
33. Y.G. Kim, J.W. Suh, C.H. Yoon, I.Y. Oh, Y.S. Cho, and T.J. Youn Platelet volume indices are associated with high residual platelet reactivity after antiplatelet therapy in patients undergoing percutaneous coronary intervention J Atheroscler Thromb 21 5 2014 445 453
34. S.G.B.R. Chu, P.B. Berger, D.L. Bhatt, J.W. Eikelboom, B. Konkle, and E.R. Mohler Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis J Thromb Haemost 8 2010 148 156
35. N. Taglieri, F. Saia, C. Rapezzi, C. Marrozzini, M.I. Bacchi Reggiani, and T. Palmerini Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome Thromb Haemost 106 2011 132 140
36. J.N. Thon, and J.E. Italiano Jr. Does size matter in platelet production? Blood 120 8 2012 1552 1561